SQXlogo
  • My Dashboard
  • Bond Academy
  • Tools
    • Bond Screener
    • Issuer Directory
    • Portfolio Builder
    • Discussion Board
  • Data Partners
‌
‌
  • Home
  • My Dashboard
  • Bond Academy
  • Tools
  • Data Partners
  • LoginCreate a free account
SQX-logo
SQX-white-logo© SQX BONDS. All rights reserved | Privacy Policy | Terms and Conditions | Represent a financial institution? | Customer Support
Visit SQXBonds on linkedinVisit SQXBonds on LinkedInVisit SQXBonds on facebookVisit SQXBonds on LinkedInVisit SQXBonds on instagramVisit SQXBonds on LinkedInVisit SQXBonds on twitterVisit SQXBonds on LinkedInVisit SQXBonds on iplVisit SQXBonds on LinkedIn
  1. Screener
  2. Issuers index
  3. T
  4. Teva Pharmaceutical Finance IV B.V.

Teva Pharmaceutical Finance IV B.V. Bonds

Teva Pharmaceutical Finance IV B.V., founded in 2016 and based in the Netherlands, is a subsidiary of Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company committed to improving health through innovative medicines and generic drugs. The company primarily focuses on the issuance of debt securities to support the financing needs of its parent organization's operations and strategic initiatives.

Bond NameCountryMaturityCoupon(%)
No data found!
Showing results 0 - 0 of 0
Per page

Company overview and issue history are AI generated, and should not be cited or relied on without verification.

Teva Pharmaceutical Finance IV B.V. issue history

Teva Pharmaceutical Finance IV B.V. began its bond issuance program shortly after its establishment, with significant issuances such as a €1.5 billion bond in 2017, aimed at refinancing existing debt and strengthening its financial position. The issuer currently offers bonds with varying maturities, featuring competitive yields compared to industry averages. In recent developments, the company announced plans to restructure its debt portfolio, which may impact future bond offerings, making it an important player in the corporate bond market amid ongoing strategic transitions.